APA (7th ed.) Citation

DZI, C., P, R., ME, C., ML, C., R, C., L, C., . . . KR, T. (2026). Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses. Diabetes, obesity & metabolism, 28(7), 6324. https://doi.org/10.1111/dom.70836

Chicago Style (17th ed.) Citation

DZI, Cherney, et al. "Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses." Diabetes, Obesity & Metabolism 28, no. 7 (2026): 6324. https://doi.org/10.1111/dom.70836.

MLA (9th ed.) Citation

DZI, Cherney, et al. "Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses." Diabetes, Obesity & Metabolism, vol. 28, no. 7, 2026, p. 6324, https://doi.org/10.1111/dom.70836.